ENG
INA
First Research-Based Doctor of Medical Science Develops Andrographolid Emulgel as an Alternative Topical Treatment for Psoriasis
First Research-Based Doctor of Medical Science Develops Andrographolid Emulgel as an Alternative Topical Treatment for Psoriasis
Located in the Postgraduate Hall, 3rd Floor of the Postgraduate Building, Udayana University, for the first time the Doctoral Study Program in Medical Science, Faculty of Medicine, Udayana University held an open examination for Research-Based Doctoral Promotion (Research) with the candidate for promovenda, dr. Indira Dharmasamitha, Sp.KK, with the dissertation title "Development of Andrographolid Extract Emulgel as a Topical Treatment for Psoriasis". (1/15/2025)
Andrographolid (AP), an anti-inflammatory bioactive compound found in sambiloto, is known to inhibit NF-κB, TNF-α, and interleukin IL-6. Currently, the results of molecular docking simulations between AP and dexamethasone against the NF-κB receptor show that the interaction energy of AP is higher compared to dexamethasone. This finding makes AP a potential treatment for psoriasis. Therefore, this dissertation aims to report the effectiveness of AP from Sambiloto in treating psoriasis compared to topical steroids. This study conducted TLC analysis of AP content and its metabolites, emulgel formulation, molecular docking, in-silico skin toxicity studies, and in-vivo anti-psoriatic activity.
This study is a combination of in-silico and in-vivo studies. This in-silico study was analyzed through multivariate statistical analysis (PCA) to explain the relationship of andrographolide derivative data constellations with several target proteins. The intervention was carried out within seven days. PASI scores, molecular parameters (IL-6, IL-17, VEGF, and TNF-a levels), and histopathological findings were assessed.
Molecular docking results showed that AP has a relatively high binding affinity to IL-6, NF-kB, and TNF-α, which is comparable to corticosteroids. In addition, AP also shows a similar residue interaction profile with each of the protein's native ligands. In the in-vivo study, we found several parameters that were statistically significantly different related to the intervention, including the final PASI score (p=0.017), redness (p=0.017), squama (p=0.040), thickness (p=0.023), total psoriasis histopathology score (p=0.037), and keratin layer score (p=0.018). In conclusion, AP emulgel 0.1% can reduce the PASI score and histopathological severity which are important in the treatment of psoriasis.
Optimization of the initial formula, more detailed Lab-scale product stability testing to study the critical control points in the development of up-scaling production in the industry including the identification of critical control points in the extraction method, until the andrographolid content is obtained according to the standard. Implementation of Up-Scaling of Andrographolid 0.1% emulgel production in collaboration with full-aspect CPOTB certified pharmaceutical partners and application of pharmaceutical parameters of the formula in industrial-scale production based on the BPOM-approved pre-clinical test protocol.
The results of this study are expected to produce a prototype product of 0.1% Andrographolid extract emulgel as an alternative to corticosteroids as a topical anti-inflammatory in the treatment of psoriasis. The results of the study will be registered with BPOM as an anti-psoriasis OHT preparation and then a simple patent will be made.
This examination was led by the Dean of the Faculty of Medicine, Udayana University, Prof. Dr. dr. Komang Januartha Putra Pinatih, M.Kes, with the following examining team:
1. Prof. apt.Dr.rer.nat.,Drs. I Made Agus Gelgel Wirasuta, M.Si. (Promoter)
2. Dr.dr.Luh Made Mas Rusyati,SpKK(K),FINSDV,FAADV. (Co-promoter I)
3. Dr. dr. Dyah Kanya Wati, Sp.A(K). (Co-promoter II)
In this examination, Dr. dr. Indira Dharmasamitha, Sp.KK, was declared to have graduated as the 441st Doctoral Graduate of the Doctoral Program in Medical Sciences, Faculty of Medicine, Udayana University with Cum Laude predicate.
UDAYANA UNIVERSITY